Featured Research

from universities, journals, and other organizations

Antiviral therapy may halve risk of liver cancer after chronic hepatitis C infection, analysis indicates

Date:
October 22, 2012
Source:
BMJ-British Medical Journal
Summary:
Treating chronic hepatitis C infection with antiviral drugs could halve the risk of developing the most common form of liver cancer, in some cases, a new analysis indicates.

Treating chronic hepatitis C infection with antiviral drugs could halve the risk of developing the most common form of liver cancer, in some cases, indicates an analysis of the published research in one of the new BMJ Open Editions.

Hepatocellular carcinoma is the most common form of liver cancer worldwide, accounting for 90 per cent of all primary cases of the disease. Cirrhosis of the liver and hepatitis C infection are among the most important risk factors.

The authors reviewed the published evidence on the use of antiviral therapy -- interferon or pegylated interferon, or ribavirin, or a combination -- in people with chronic hepatitis C infection, to assess its impact, and to see if the level of viral clearance, prompted by the treatment, made any difference.

In some people, antiviral treatment helps the body clear the virus; in others an initial response is followed by a relapse a few months later. If treatment succeeds in keeping the virus at bay for six months, the chances of relapse are miniscule.

The authors reviewed the data from 8 comparative treatment trials of those whose hepatitis C infection had resulted in chronic inflammation and fibrosis (gristle) or cirrhosis (scarring and limited working capacity) of the liver.

And they also included data from five prospective cohort studies, which regularly monitor similar groups of people over the long term to see what happens to them.

In all, more than 3200 people were included in the analysis. Their treatment, which was predominantly interferon, lasted between 6 months and a year, and they were monitored for periods of between five and eight years.

In the trials, a total of 1156 people were treated with antiviral therapy, 81 of whom developed liver cancer; and 1174 were not, 129 of whom developed the disease -- equivalent to a reduction in risk of 47 per cent.

Those in whom treatment cleared the virus, long term, were 85 per cent less likely to develop liver cancer compared with those in whom treatment was less effective. Nevertheless this group were still 43 per cent less likely to develop liver cancer.

The observational (cohort) study data also showed that antiviral therapy curbed the risk of liver cancer by around 70 per cent compared with those not given the treatment.

The authors caution that the length of monitoring and the lack of information on death rates could mean that treatment with interferon may simply delay, rather than prevent, liver cancer in infected patients.

But they point out that standard treatment now consists of interferon plus ribavirin, which is deemed more effective, and that the infection tends to be picked up earlier before it has had time to do wreak long term damage.


Story Source:

The above story is based on materials provided by BMJ-British Medical Journal. Note: Materials may be edited for content and length.


Journal Reference:

  1. N. Kimer, E. K. Dahl, L. L. Gluud, A. Krag. Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials. BMJ Open, 2012; 2 (5): e001313 DOI: 10.1136/bmjopen-2012-001313

Cite This Page:

BMJ-British Medical Journal. "Antiviral therapy may halve risk of liver cancer after chronic hepatitis C infection, analysis indicates." ScienceDaily. ScienceDaily, 22 October 2012. <www.sciencedaily.com/releases/2012/10/121022192421.htm>.
BMJ-British Medical Journal. (2012, October 22). Antiviral therapy may halve risk of liver cancer after chronic hepatitis C infection, analysis indicates. ScienceDaily. Retrieved July 26, 2014 from www.sciencedaily.com/releases/2012/10/121022192421.htm
BMJ-British Medical Journal. "Antiviral therapy may halve risk of liver cancer after chronic hepatitis C infection, analysis indicates." ScienceDaily. www.sciencedaily.com/releases/2012/10/121022192421.htm (accessed July 26, 2014).

Share This




More Health & Medicine News

Saturday, July 26, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins